CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Repaglinide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06165146
NCT06165146Phase 1Completed
CompareCT.gov

A Phase I, Open-label, Fixed-sequence, Drug Interaction Study to Investigate the Effect of Multiple Oral Doses of Pirtobrutinib (LOXO-305) on the Pharmacokinetics of Repaglinide (CYP2C8 Substrate) in Healthy Subjects

Eli Lilly and Company·interventional·Posted Dec 11, 2023·Updated Mar 17, 2025

In Brief

A Phase 1 clinical trial evaluating Repaglinide and Pirtobrutinib for Healthy. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) in adult healthy participants. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). The study is conducted in two periods. Participants will stay in this study for up to 54 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedDec 11, 2023
Enrollment StartNov 10, 2020
Primary CompletionDec 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.6 years ago

Interventions

Repaglinidedrug

Administered orally.

Pirtobrutinibdrug

Administered orally.